Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival.

Nat Med · 2025 · PMC11835752 · PMID 39753968

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significanceP = 0.2not close (p > 0.1)

While KRAS mutant gains were more frequent in RNF43 MUT tumors, this did not reach statistical significance in our cohort (67% of RNF43 MUT tumors had KRAS mutant gains versus 30% in RNF43 WT , P = 0.2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.